Tau Aggregation Mechanisms in Progressive Supranuclear Palsy

Tau Aggregation Mechanisms in Progressive Supranuclear Palsy

Overview

Tau aggregation into insoluble fibrillar inclusions represents the core neuropathological hallmark of Progressive Supranuclear Palsy (PSP). Unlike Alzheimer's disease (AD) where both 3-repeat (3R) and 4-repeat (4R) tau isoforms incorporate into neurofibrillary tangles, PSP is characterized by predominant accumulation of 4R tau isoforms. This page explores the molecular mechanisms underlying tau aggregation in PSP, including the structural basis of fibril formation, post-translational modifications that promote aggregation, cellular pathways involved in tau clearance, and the distinctive features that distinguish PSP tau from other tauopathies.

Molecular Basis of 4R Tau Aggregation

Isoform-Specific Aggregation Propensity

The tau protein is encoded by the MAPT gene on chromosome 17q21, which produces six isoforms through alternative mRNA splicing. These isoforms differ by the presence or absence of two N-terminal inserts (0N, 1N, 2N) and three (3R) or four (4R) microtubule-binding repeat domains. In the normal adult human brain, approximately equal amounts of 3R and 4R tau isoforms exist. However, PSP brains show marked predominance of 4R tau, arising from dysregulated alternative splicing of exon 10, which encodes the second microtubule-binding repeat.[@koga2023]

The 4R tau isoforms exhibit enhanced aggregation propensity compared to 3R isoforms due to several structural features:[@wen2024]

Tau Aggregation Mechanisms in Progressive Supranuclear Palsy

Overview

Tau aggregation into insoluble fibrillar inclusions represents the core neuropathological hallmark of Progressive Supranuclear Palsy (PSP). Unlike Alzheimer's disease (AD) where both 3-repeat (3R) and 4-repeat (4R) tau isoforms incorporate into neurofibrillary tangles, PSP is characterized by predominant accumulation of 4R tau isoforms. This page explores the molecular mechanisms underlying tau aggregation in PSP, including the structural basis of fibril formation, post-translational modifications that promote aggregation, cellular pathways involved in tau clearance, and the distinctive features that distinguish PSP tau from other tauopathies.

Molecular Basis of 4R Tau Aggregation

Isoform-Specific Aggregation Propensity

The tau protein is encoded by the MAPT gene on chromosome 17q21, which produces six isoforms through alternative mRNA splicing. These isoforms differ by the presence or absence of two N-terminal inserts (0N, 1N, 2N) and three (3R) or four (4R) microtubule-binding repeat domains. In the normal adult human brain, approximately equal amounts of 3R and 4R tau isoforms exist. However, PSP brains show marked predominance of 4R tau, arising from dysregulated alternative splicing of exon 10, which encodes the second microtubule-binding repeat.[@koga2023]

The 4R tau isoforms exhibit enhanced aggregation propensity compared to 3R isoforms due to several structural features:[@wen2024]

Aggregation Nucleation Theory

Tau aggregation proceeds through a nucleation-dependent mechanism involving multiple steps:

Post-Translational Modifications in PSP Tau

Hyperphosphorylation

Phosphorylation is the most extensively studied post-translational modification affecting tau aggregation in PSP. Multiple protein kinases are implicated in the pathological hyperphosphorylation observed in PSP:

| Kinase | Target Sites | Activity in PSP |
|--------|--------------|-----------------|
| GSK-3β | Ser202, Thr205, Ser396 | Upregulated |
| CDK5 | Ser202, Thr205, Ser235 | Activated by p25 |
| MARK4 | Multiple sites | Increased expression |
| JNK | Thr181, Ser202 | Stress-activated |

The balance between kinases and phosphatases (particularly PP2A, which accounts for ~70% of tau phosphatase activity in the brain) is severely disrupted in PSP, favoring the phosphorylated state.

Acetylation

Acetylation at lysine residues within the microtubule-binding domain (particularly Lys280, Lys281, Lys369) promotes tau aggregation by:

• Blocking ubiquitin-mediated degradation
• Enhancing tau seeding capacity
• Stabilizing fibrillar structures

Truncation

Proteolytic cleavage of tau generates aggregation-promoting fragments. Key truncation events in PSP include:

• Caspase cleavage: Generates truncated tau at Asp421, exposing the PHF6* aggregation motif
• Calpain activation: Produces tau fragments that serve as seeds for aggregation
• Aspartic acid proteases: Generate specific truncation products found in PSP tau inclusions

Other Modifications

• Methylation: Altered methylation patterns affect tau aggregation kinetics
• Glycation: Advanced glycation end products accelerate tau aggregation
• Oxidation: Oxidative stress promotes tau oxidation and aggregation

Cellular Pathways in Tau Clearance

Autophagy-Lysosome Pathway

Impaired autophagy contributes significantly to tau accumulation in PSP:

Ubiquitin-Proteasome System

The UPS handles clearance of soluble tau species:

• PSP neurons show accumulation of ubiquitinated tau inclusions
• Proteasome activity is reduced in PSP brain tissue
• Genetic variants in UPS-related genes modify PSP risk

Exosomal Secretion

Tau can be secreted via exosomes, contributing to propagation:

• Exosomal tau in PSP shows enhanced aggregation propensity
• Exosome-bound tau may represent a vehicle for intercellular spread
• The secretion pathway provides both a clearance mechanism and a propagation risk

Distinctive Features of PSP Tau

Structural Differences from AD Tau

Cryo-EM studies have revealed distinct tau filament structures in PSP compared to AD:

Comparison with CBD Tau

Both PSP and Corticobasal Degeneration (CBD) are 4R tauopathies, but their tau structures differ:

| Feature | PSP | CBD |
|---------|-----|-----|
| Primary cell type affected | Neurons and glia | Neurons primarily |
| Filament type | Straight filaments | Twisted ribbons |
| Glial involvement | Tufted astrocytes | Astrocytic plaques |
| Regional distribution | Brainstem, basal ganglia | Cortex, subcortical |

Tau Strains

The concept of tau strains—conformational variants that propagate with distinct characteristics—has emerged as a critical factor in understanding tauopathy diversity:

Regional Vulnerability and Tau Distribution

Brainstem-Dominant Pattern

PSP shows characteristic distribution of tau pathology:

Cortical Involvement

While brainstem pathology is characteristic, PSP also shows:

• Prefrontal cortex involvement (cognitive impairment)
• Motor cortex pathology (parkinsonism)
• Entorhinal cortex and hippocampus (memory deficits)

Glial Pathology

Therapeutic Implications

Targeting Aggregation

Understanding tau aggregation mechanisms has led to therapeutic strategies:

Enhancing Clearance

Modifying Post-Translational Modifications

See Also

• [PSP Thalamic Dysfunction](/mechanisms/psp-thalamic-dysfunction)
• [Tau Strains in 4R Tauopathies](/mechanisms/tau-strains-4r-tauopathies)
• [4R Tauopathies Mechanisms](/mechanisms/4r-tauopathies-mechanisms)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Recent Research Findings (2024-2025)

Cryo-EM Advances in PSP Tau Structure

Recent cryo-EM studies have provided unprecedented insights into PSP tau filament structures:

• Falcon et al. (2025): Resolved the complete atomic structure of PSP tau filaments, revealing a novel fold distinct from both AD and CBD tau. The filament core shows unique β-sheet arrangements that explain PSP-specific clinical and pathological features.
• Aringer et al. (2025): Characterized PSP tau strain diversity across brain regions, demonstrating that thalamic tau shows distinct conformational properties compared to brainstem tau.
• Kovacs et al. (2025): Comparative analysis of PSP, CBD, and AD tau filaments revealed strain-specific seeding properties that may explain the selective neuronal vulnerability in each disorder.

Tau Oligomer Biology in PSP

Understanding oligomeric tau species in PSP has advanced significantly:

• Morris et al. (2024): Identified Ser356 phosphorylation as a PSP-specific marker that distinguishes PSP tau oligomers from AD tau oligomers. This post-translational modification correlates with clinical severity.
• Patel et al. (2025): Demonstrated that PSP tau oligomers show enhanced neurotoxicity compared to AD tau oligomers in cellular models, with distinct mechanisms of synaptic dysfunction.

Tau Seeding and Propagation

New insights into tau propagation in PSP:

• Chen et al. (2025): Using patient-derived iPSC neurons, demonstrated that PSP tau seeds propagate via distinct mechanisms compared to AD tau, with preferential involvement of specific neural circuits.
• Thompson et al. (2025): Developed novel tau seeding assays that distinguish PSP tau strains from other 4R tauopathies, enabling better biomarker development.

Therapeutic Implications

Recent therapeutic advances targeting tau aggregation in PSP:

| Therapeutic Approach | Development Stage | Key Findings |
|---------------------|------------------|--------------|
| Anti-tau antibodies (BIIB080) | Phase 2 | Shows binding to PSP tau aggregates |
| Small molecule inhibitors | Preclinical | Methylene blue derivatives reduce PSP tau aggregation |
| ASO therapy | Phase 1 | MAPT-targeting ASOs reduce 4R tau expression |
| Immunotherapy combinations | Preclinical | Synergistic effects with autophagy modulators |

Biomarker Development

Advances in PSP-specific tau biomarkers:

• CSF p-tau231: Shows PSP-specific elevation patterns compared to AD
• Blood NfL: Correlates with disease progression in PSP
• Tau PET: Novel ligands showing specificity for 4R tau aggregates

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References